Table 2.
Clinical characteristics of participants in the discovery cohort.
| Severe ALD (n=9) | Health control (n=9) | P value | |
|---|---|---|---|
| Age | 42.72 ± 5.31 | 37.18 ± 2.37 | 0.14 |
| Gender | men | men | / |
| ALT (U/L) | 16.90 (13.65, 22.50) | 12.20 (10.40, 16.85) | 0.171 |
| AST (U/L) | 24.80 (16.55, 36.40) | 16.22 ± 2.86 | 0.047 |
| ALB (g/L) | 38.23 ± 4.02 | 47.18 ± 1.89 | 0.014 |
| Tbil (µmol/L) | 17.20 (7.45, 34.95) | 11.43 ± 3.47 | 0.251 |
| ALP (U/L) | 88.04 ± 25.42 | 70.20 (62.35, 97.30) | 0.310 |
| GGT (U/L) | 80.84 ± 94.17 | 13.00 ± 4.08 | 0.001 |
| PLT (109/L) | 83 ± 49 | 230 ± 38 | 0.001 |
| APRI | 0.34 ± 0.21 | 0.07 ± 0.02 | 0.051 |
| FIB-4 | 4.82 ± 2.30 | 0.65 ± 0.14 | 0.04 |
| AAR | 1.69 ± 0.63 | 1.20 ± 0.32 | 0.085 |